Analysis of CASP12 diagnostic and prognostic values in cervical cancer based on TCGA database

Abstract

The present study aims to find a differential protein-coding gene caspase 12 (CASP12) in cervical cancer (CC) based on the (TCGA) database and verify its clinical diagnostic and prognostic values. The transcriptome and clinicopathological data of CC were downloaded from the TCGA database and through screening, we found that PDE2A and CASP12 were independent prognostic factors for CC patients. According to the median expression, the patients were divided into groups with high and low CASP12 and PDE2A expression. There was no difference in survival between PDE2A high and low expression groups (P=0.099), whereas there was a significant difference between CASP12 high and low expression groups (P=0.033). The serum from 68 CC patients (experimental group) and 50 healthy people (control group) was collected to detect the relative expression of CASP12 using qRT-PCR and plotted the ROC curve. The relative expression of CASP12 in the experimental group was significantly lower than in the control group (P<0.05). The area under the curve (AUC) of CASP12 was 0.865. There were statistically significant differences between CASP12 groups with high and low expression in terms of differentiation, lymph node metastasis, tumor size, FIGO staging, and clinical outcomes (P<0.05), but not in terms of age, HPV types and pathological types (P>0.05). The 3-year survival in the CASP12 low expression group was significantly worse than in the CASP12 high expression group (P=0.028). In conclusion, the expression level of CASP12 can be used as a diagnostic and prognostic biomarker for patients with CC.

Establishment of a Prognostic Stemness Signature For Cervical Squamous Cell Carcinoma

“…The dysregulated transcription of cancer cells frequently leads to the acquisition of stemness characteristics as well as de-differentiation of oncogenes through altering key signaling pathways that regulate the phenotypes of normal stem cells (17)(18)(19). Over the last one decade, The Cancer Genome Atlas (TCGA) and the GEO databases have displayed the landscapes of primary cancers through generating the comprehensive molecular pro les comprised of histopathological and clinical annotations, together with the genomic, epigenomic, transcriptomic and post-translational proteomic characteristics (20,21). The Progenitor Cell Biology Consortium (PCBC) database (22) covers the expression pro les of the embryonic stem cells (ESCs) and the induced pluripotent stem cells (iPSCs), which can be used for identifying the CSCC stemness genes in later analysis.…”

Establishment of a Prognostic Stemness Signature for Cervical Squamous Cell Carcinoma

“…The dysregulated transcription of cancer cells frequently leads to the acquisition of stemness characteristics as well as de-differentiation of oncogenes through altering key signaling pathways that regulate the phenotypes of normal stem cells (17)(18)(19). Over the last one decade, The Cancer Genome Atlas (TCGA) and the GEO databases have displayed the landscapes of primary cancers through generating the comprehensive molecular pro les comprised of histopathological and clinical annotations, together with the genomic, epigenomic, transcriptomic and post-translational proteomic characteristics (20,21). The Progenitor Cell Biology Consortium (PCBC) database (22) covers the expression pro les of the embryonic stem cells (ESCs) and the induced pluripotent stem cells (iPSCs), which can be used for identifying the CSCC stemness genes in later analysis.…”